Chimeric antigen receptors targeting GPC3 and uses thereof

US10731127B2 · kind B2 · utility

Assignee

• CARSGEN THERAPEUTICS CO., LTD. · CN

Inventors

• Zonghai LI · Shanghai, CN
• Huiping Gao · Shanghai, CN
• Hua Jiang · Shanghai, CN
• Bizhi Shi · Shanghai, CN
• Huamao WANG · Shanghai, CN
• Kesang Li · Shanghai, CN
• Hongyang Wang · Hefei, CN
• Shengli Yang · 安丰镇, CN
• Jianren Gu · Shanghai, CN

Key dates

• Filing date: May 6, 2014
• Grant date: Aug 4, 2020
• Expiry date: Aug 3, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.